Abstract 177P
Background
Mutation-derived neoantigens, usually identified from the primary cancer, are being targeted by vaccination in clinical trials. However, clinical success in patients with extensive metastatic disease is limited, possibly due to poor neoantigen selection. Targeting ubiquitous neoantigens - present in all metastatic sites - is appealing. We investigated the presence of ubiquitous neoantigens and their T-cell recognition in a patient with treatment-naïve metastatic pancreatic neuroendocrine tumour (PNET), analysing the primary tumour and 13 synchronous nodal metastases.
Methods
Bulk RNA sequencing, whole exome sequencing and mutation calling were performed on all samples; β-chain T-cell receptor (TCR) sequencing was performed on eight metastatic sites. Mutation-associated long peptides (MUT_LPs) and predicted minimal neoepitopes (MUT_ME) were synthesized. IFN-γ ELISpot and single-cell RNA/TCR sequencing (scRNA/TCRseq) were undertaken on MUT_LPs/MEs stimulated peripheral blood mononuclear cells (PBMCs) after in vitro expansion. ScTCRseq was performed on MUT_ME-MHC class I tetramer-positive CD8 T-cells. TCR overlap was evaluated between metastatic sites, MUT_LP/ME expanded and tetramer-positive T-cells.
Results
We identified a median of 88 non-synonymous mutations (range 64-204) per site, indicating low tumour-mutation burden (TMB). Seven mutations were identified in all metastatic sites. T cell recognition was shown by ELISpot for two MUT_LPs and one MUT_ME (MUT_NPTX2). scRNAseq of MUT_NPTX2_ME/LP-expanded PBMCs showed activated CD8 T-cells; 94.8% of these cells had TCRs matching MUT_NPTX2_ME-MHC class I tetramer-positive clones. Putative MUT_NPTX2-reactive CD8 T-cells were found in all analysed metastatic sites (1.9%-7.0% of reads per site), with evidence of expansion.
Conclusions
In a low TMB setting, we found seven ubiquitous mutations. One neoantigen showed T-cell recognition, with reactive T-cells present in all analysed metastatic sites. This novel finding suggests that ubiquitous neoantigens-targeting vaccines, possibly combined with immune-checkpoint inhibitors, could be promising for patients with extensive metastatic PNET.
Legal entity responsible for the study
Prof. Christian Ottensmeier.
Funding
Whittaker Fund.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
7P - ACOX2 disturbs the stability of MRE11-RAD50-NBS1 complex and shapes activated immune tumor microenvironment in clear cell renal cell carcinoma
Presenter: Shiqi Ye
Session: Poster Display session
Resources:
Abstract
9P - CXCR6+PD-1- Tissue Resident memory T cells are associated with poor prognosis in patients with metastatic colorectal cancer
Presenter: Emilien Laloy
Session: Poster Display session
Resources:
Abstract
10P - Tumor-infiltrating lymphocytes and tertiary lymphoid structures in oral cavity squamous cell carcinoma in non-smokers and non-drinkers: Predict clinical outcome
Presenter: Israa Laklouk
Session: Poster Display session
Resources:
Abstract
11P - Tumor-infiltrating lymphocytes on routine H&E staining with automated quantification predict outcomes in resectable non-small cell lung cancer
Presenter: Guus Heuvel
Session: Poster Display session
Resources:
Abstract
12P - Epithelial-mesenchymal transition facilitates response to AXL/PD-1 inhibition in relapsed mesothelioma
Presenter: Essa Baitei
Session: Poster Display session
Resources:
Abstract
14P - Integrated genomic analysis of whole genomes to derive a biomarker of durable response to immunotherapy in melanoma
Presenter: Irene Lobon
Session: Poster Display session
Resources:
Abstract
15P - Verteporfin might potentiate the effects of anti-PD-1 therapy in melanoma-bearing mice model
Presenter: Szonja Kovács
Session: Poster Display session
Resources:
Abstract
16P - Immune checkpoint blockade and HLA-related epistasis in melanoma: Genetic determinants of response and toxicity
Presenter: Martin Little
Session: Poster Display session
Resources:
Abstract
17P - Identification PD-L1-associated lncRNA biomarkers for immunoregulation in ovarian cancer
Presenter: Hee Jung Kim
Session: Poster Display session
Resources:
Abstract
19P - Genetic profiling of early triple-negative breast cancer patients with an indication for neoadjuvant pembrolizumab
Presenter: Bogdan Popescu
Session: Poster Display session
Resources:
Abstract